November 12-14, 2018
Boston, MA
View 2018 Finalized Agenda

 

Day One
TUESDAY, NOVEMBER 13 2018

Day Two
WEDNESDAY, NOVEMBER 14 2018

08.20
Registration & Morning Coffee

09.20
Chairperson Opening Remarks

Infant Health Modulation through Microbes

09.30
From Dysbiosis to Recovery in the Infant Gut Microbiome: A New Paradigm in Infant Nutrition

  • David Kyle Chief Scientific Officer, Evolve Biosystems

Synopsis

  • The natural infant gut microbiome is defined by the HMOs in breast milk and me
  • This keystone commensal organism has been generationally lost in the developed world through the unintended consequences of modern medical practices
  • Evolve has demonstrated that this natural infant gut microbiome can be reestablished and has launched the first gut microbiome remodelling product of its kind

10.00
Human Milk Oligosaccharides (HMOs) Nature’s Prebiotics for a Healthy Infant Microbiome

Synopsis

  • More than 100 years ago the Human Milk Oligosaccharides (HMOs) research laid the foundation of our current view of pre- and probiotics
  • HMOs selectively promote the growth of “beneficial” bacteria ( i.e. promotes a healthy microbiome) in infants
  • HMOs are finally available for food and medical applications, in particular for Infant formula application

Microbes & Mental Health – Harnessing the Gut-Brain Axis Through Nutrition

10.15
Connecting the Gut Microbiota to Diet, Metabolism, Neural Activity and Behaviour to Develop Effective Microbiota- Based Treatments for Epilepsy and Improved Brain Health

10.45
Morning Refreshments & Networking

Human Study Design/Clinical/Broader Product Development – Building Stronger Claims to Differentiate your Product

11.15
How Microbiome Data Can Complement Other Clinical Endpoints to Aid in Health Improvement

11.45
Delivery, Survival, Engraftment & Activity of LBPs in the Gastrointestinal Tract

Synopsis

  • Validated in-vitro technology platforms are a key tool for the pre-clinical work in LBPs development
  • The SHIME® is an enabling technology which allows an integrated simulation of the
    full GI tract, including lumen, mucosa and host
  • The SHIME® allows you to investigate the mechanism of action of LBPs in areas of the gut, which is not easily accessible, generating data complementary to in vivo studies

12.15
Lunch & Networking

Regulatory Guidance – Challenges for Microbiome Claims in Health & Wellness

13.15
Aligning Regulatory Frameworks, Consumer Insights and R&D for Successful Probiotic Claims and Communications

Sports Performance, Recovery & the Microbiome

13.45
Promoting Peak Performance: Identifying and Isolating Novel Probiotics from Athlete Microbiomes

Synopsis

  • Demonstrating results of pre-clinical studies into a novel probiotic candidate that can break down lactic acid
  • Providing evidence for athletes’ distinct microbial communities and the dynamic behavior of those communities during sports performance and recovery
  • Learn how next-generation sequencing can identify novel probiotic species and strains

14.15
Chairperson’s Closing Remarks

Close of 2nd Microbiome Movement – Human Nutrition Summit 2018